SML0527

Epalrestat

≥98% (HPLC)

• Synonyme(s) : (5Z)-5-[(2E)-2-Methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid
• Formule empirique (notation de Hill) : C₁₅H₁₃NO₃S₂
• Numéro CAS: 82159-09-9
• Poids moléculaire : 319.40
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder
• Storage condition: protect from light

Propriétés

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• storage condition: protect from light
• color: yellow to orange
• solubility: DMSO: 5 mg/mL, clear (warmed)
• storage temp.: −20°C
• SMILES string: S1\C(=C/C(=C/c2ccccc2)/C)\C(=O)N(C1=S)CC(=O)O
• InChI: 1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-
• InChI key: CHNUOJQWGUIOLD-NFZZJPOKSA-N

Description

Application

Epalrestat has been used as an aldose reductase inhibitor:

• in the dahomey larvae diet fed forDrosophila
• for non-irradiated and X-ray irradiated human aldose reductase
• to test its protective effect in mice with bleomycin-induced pulmonary fibrosis

Biochem/physiol Actions

Epalrestat inhibits Aldose Reductase (AR) involved in the rate limiting step in the conversion of glucose to sorbitol under hyperglycemic conditions. Aldose reductase has been the target of multiple clinical investigatons to treat diabetic neuropathy and retinopathy. Epalrestat is an approved drug in Japan and India, used for the treatment of diabetic neuropathy.

Epalrestat is an Aldose Reductase inhibitor.

Features and Benefits

This compound is featured on the Dopamine and Norepinephrine Metabolism page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Other Notes

Light sensitve

Informations sur la sécurité

• Classe de stockage: 11 - Combustible Solids
• Que se passe-t-il ?: WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable